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Infect ions  from mult idrug- resistant gram-positive bacteria continue to be a burden to society 
and are associated with high morbid-
ity and mortality.1-3 Some of the most 
concerning of these pathogens include 
methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin- 
resistant enterococci (VRE).
Since MRSA was first described 
in the 1960s, it has become more 
widespread—first in hospitals and 
later in the community setting. From 
1999 to 2005, there was a 62% in-
crease in hospitalizations involving 
S. aureus infections, with MRSA- 
related infections increasing over 
twofold (from approximately 127,000 
to 278,000 infections per year).1 
However, 2005–08 surveillance data 
demonstrated a 28% decrease in 
hospital-onset invasive MRSA in-
fections and a 17% decrease in 
health care–associated community- 
onset cases during that period.3 De-
spite this improvement, there still 
remains a large burden of disease 
and the need for new safe and effec-
tive agents to combat these organ-
isms. For decades, vancomycin has 
been the cornerstone of therapy for 
invasive MRSA infections. However, 
recent studies have demonstrated 
Purpose. The mechanism of action, phar-
macokinetics, pharmacodynamics, and 
clinical efficacy and safety of an investiga-
tional second-generation oxazolidinone 
are reviewed.
Summary. Tedizolid is a protein synthesis 
inhibitor in clinical development for the 
treatment of gram-positive infections. 
Similar to linezolid, tedizolid works by bind-
ing to the 23S ribosomal RNA of the 50S 
subunit, thereby preventing the formation 
of the 70S initiation complex and inhibit-
ing protein synthesis. Tedizolid has dem-
onstrated potent in vitro activity against 
multidrug-resistant gram-positive bacteria 
such as methicillin-resistant Staphylococcus 
aureus (MRSA), Streptococcus pneumoniae, 
and vancomycin-resistant enterococci 
(VRE), including some linezolid-resistant 
strains. Tedizolid has a favorable pharma-
cokinetic profile that allows for once-daily 
dosing and easy i.v.-to-oral conversion. 
Unlike linezolid, tedizolid has not been 
shown to interact with serotonergic agents 
in clinical studies. Two Phase III studies in 
patients with acute bacterial skin and skin 
structure infections have demonstrated the 
noninferiority of 6 days of tedizolid therapy 
(200 mg i.v. or orally once daily) relative to 
10 days of linezolid therapy. In clinical trials 
to date, overall rates of treatment-related 
adverse effects with linezolid and tedizolid 
were comparable (40.8% versus 43.3%), 
with nausea being the most commonly 
reported adverse effect associated with te-
dizolid use (16% of patients). Planned stud-
ies will investigate tedizolid’s potential role 
in the treatment of community-acquired 
bacterial pneumonia, hospital-acquired/
ventilator-associated bacterial pneumonia, 
and bacteremia.
Conclusion. Tedizolid is an investigational 
oxazolidinone antibiotic for the treat-
ment of multidrug-resistant gram-positive 
pathogens such as MRSA, Streptococcus 
pneumoniae, and VRE, including some 
linezolid-resistant strains.
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increases in vancomycin minimum 
inhibitory concentrations (MICs) 
for some MRSA strains, including 
vancomycin-intermediate and het-
eroresistant strains, and reports of 
clinical failures with vancomycin 
have increased.4-7
Enterococci are common patho-
gens in urinary tract infections and 
endocarditis and remain a common 
cause of nosocomial infections de-
spite the use of rigorous infection 
control measures.8-10 One of the 
biggest challenges in combating en-
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terococci is that they are inherently 
resistant to most classes of antibiot-
ics, including all commercially avail-
able cephalosporins.8,9 In addition, 
enterococci have the ability to de-
velop resistance through mutations 
and through the transfer of plasmids 
and transposons from other bacte-
ria. VRE were first described in the 
late 1980s and spread rapidly in the 
United States and Europe.9 With van-
comycin no longer a viable therapy in 
these patients, there are few options 
in the antimicrobial arsenal that are 
both safe and effective.
In April 2000, linezolid, the first 
of a new class of antibiotics called 
oxazolidinones, was approved by 
the Food and Drug Administration 
(FDA) for the treatment of serious 
gram-positive infections, including 
MRSA, VRE, and Streptococcus pneu-
moniae.11,12 Its unique mechanism 
of action, the availability of i.v. and 
oral formulations, and its potent 
in vitro activity made linezolid a 
good alternative for the treatment of 
these difficult infections. However, 
some of the limitations of linezolid 
include the need for twice-daily dos-
ing, drug interaction potential (with 
serotonergic agents), and concern 
for bone marrow suppression with 
prolonged therapy.12 In addition, 
reports of linezolid-resistant strains of 
S. aureus and enterococci were re-
ported shortly after it became avail-
able on the market.13-15
Tedizolid (te diz′ oh lid), formerly 
torezolid, is a second-generation 
oxazolidinone under clinical devel-
opment by Cubist Pharmaceuticals 
for the treatment of serious gram- 
positive infections. Tedizolid has 
been investigated for the treatment of 
acute bacterial skin and skin structure 
infection (ABSSSI), with additional 
studies planned in patients with 
hospital-acquired and ventilator- 
associated bacterial pneumonia 
(HABP/VABP).16 In early 2013, FDA 
designated tedizolid as a “qualified 
infectious disease product,” a des-
ignation that was created by the 
Generating Antibiotic Incentives 
Now (GAIN) Act to provide pharma-
ceutical companies with incentives to 
promote the development of antibac-
terial and antifungal drugs to combat 
drug-resistant pathogens.16 These 
incentives include priority reviews 
for new drug applications (NDAs) 
and an additional five years of mar-
ket exclusivity. This article reviews 
the pharmacology, in vitro activity, 
clinical efficacy, safety, and potential 
role of tedizolid in the treatment of 
gram-positive infections.
Chemistry and pharmacology
Tedizolid phosphate (TR-701) is 
an inactive prodrug that is chemically 
converted by serum phosphatases to 
the active form tedizolid (TR-700; 
2-oxazolidinone, 3-[3-fluoro-4-[6-(2-
methyl-2H-tetrazol-5-yl)-3-pyridinyl]
phenyl]-5-(hydroxymethyl)-, (5R)), 
a synthetic second-generation oxa-
zolidinone.17 Like linezolid, tedizolid 
works by binding to the 23S ribo-
somal RNA (rRNA) of the 50S sub-
unit, thereby preventing the forma-
tion of the 70S initiation complex 
and inhibiting protein synthesis18,19; 
key structural differences from line-
zolid include a hydroxymethyl group 
in place of the acetamide group at the 
C-5 position and a d-ring substituent 
(tetrazol), which is lacking with line- 
zolid. These changes may increase 
the interaction of tedizolid with the 
peptidyl-transferase-center binding 
site and increase potency against re-
sistant bacterial strains, in some cases 
twofold to eightfold.19 Because of the 
unique mechanism of action of oxa-
zolidinones, cross-resistance with oth-
er classes of antimicrobials is unlikely.
Spectrum of activity
Tedizolid is active against gram-
positive organisms, including staphy-
lococci, streptococci, enterococci, 
and certain anaerobes.20 Table 1 
shows the inhibitory activity of te-
dizolid in vitro.20-29 Tedizolid usually 
demonstrated at least fourfold higher 
potency compared with linezolid 
for all bacteria tested.20 Several in 
vitro studies also demonstrated the 
activity of tedizolid against linezolid-
resistant bacteria.24-27
While clinical breakpoints have 
not been established for tedizolid, 
one study suggested breakpoints as 
well as interpretive criteria for disk-
diffusion methods of susceptibility 
testing.21 For all staphylococci, the 
recommended breakpoints were 
≤2, 4, and ≥8 mg/mL for susceptible, 
intermediate, and resistant bacterial 
strains, respectively. The suggested 
susceptible breakpoint for entero-
cocci, streptococci, Corynebacterium 
jeikeium, and Listeria monocytogenes 
was ≤2 mg/mL, with no intermediate 
and resistant categories. No recom-
mended MIC range was given for 
Moraxella catarrhalis or Haemophilus 
influenzae. 
Tedizolid has been shown to have 
good in vitro activity against staphy-
lococci in multiple studies.20,24,28 In 
an in vitro study involving clinical 
isolates from patients in a Phase II 
study, the MIC of tedizolid for 90% of 
isolates (MIC
90
) against 163 S. aureus 
isolates was 0.25 mg/mL.28 The range 
of tedizolid MICs against coagulase-
negative staphylococci (CoNS) was 
0.12–0.25 mg/mL. All 163 isolates were 
deemed susceptible to linezolid based 
on the Clinical Laboratory Standards 
Institute MIC breakpoints. In a sepa-
rate study, the MICs of tedizolid for 
linezolid-susceptible MRSA strains 
were 0.25–0.5 mg/mL, compared with 
linezolid MICs of 2–4 mg/mL.24 In 
another study, the tedizolid MIC
90
 was 
0.5 mg/mL for methicillin-sensitive 
S. aureus (MSSA), MRSA (includ-
ing community-acquired MRSA), 
methicillin-sensitive Staphylococcus 
epidermidis, and methicillin-resistant 
S. epidermidis.20 All staphylococci test-
ed in these studies would be deemed 
susceptible if the proposed breakpoint 
of ≤2 mg/mL were applied.21
Tedizolid also possesses activity 
against linezolid-resistant staphylo-
cocci. In an in vitro study, tedizolid 
was evaluated against 169 linezolid-
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resistant staphylococci isolates (164 
CoNS and 5 S. aureus isolates).25 The 
tedizolid MIC for all S. aureus iso-
lates was 0.5 mg/mL, compared with 
a linezolid MIC of 8–16 mg/mL. The 
tedizolid MIC
90
 for most CoNS iso-
lates was 8 mg/mL; for 2 isolates, the 
MIC was 16 mg/mL. In another in vi-
tro study evaluating tedizolid against 
linezolid-resistant staphylococci iso-
lates, the MIC
90
 values for tedizolid 
against S. aureus and S. epidermidis 
were 2 and 8 mg/mL, respectively26; 
the corresponding MIC
90
 values 
for linezolid were 16 and over 128 
mg/mL. A third in vitro study tested 
linezolid-resistant MRSA strains 
and determined tedizolid MICs of 
1–4 mg/mL, compared with MICs 
of 8–32 mg/mL for linezolid.24 For 
linezolid-resistant CoNS in the same 
study, the MICs were determined 
to be 2–4 mg/mL with tedizolid and 
32–64 mg/mL with linezolid. A final 
in vitro study showed that the me-
dian MIC of tedizolid for staphylo-
cocci was 4 mg/mL, compared with 
a median linezolid MIC of 16 mg/mL 
in linezolid-nonsusceptible staphy-
lococcal isolates.27 Therefore, some 
in vitro studies have shown tedizolid 
MICs for linezolid-resistant isolates 
that are in the range of the proposed 
susceptible breakpoints, while others 
have demonstrated higher MICs in 
the intermediate or resistant range.21
Tedizolid is active against entero-
cocci and streptococci as well. In one 
study, the tedizolid MIC
90
 values were 
1 mg/mL for vancomycin-susceptible 
enterococci and 0.5 mg/mL for 
VRE.20 In another study, the tedizolid 
MICs for linezolid-susceptible en-
terococci were 0.25–0.5 mg/mL, 
values that were within the suscep-
tible range based on the aforemen-
tioned proposed breakpoints.21,24 For 
linezolid-resistant enterococci, MICs 
were determined to be 1–16 mg/mL 
with tedizolid versus 4–64 mg/mL 
with linezolid.24 In a third study, the 
MIC
90
 of tedizolid against linezolid-
resistant enterococci was 4 mg/mL 
(nonsusceptible based on the pro-
posed breakpoints21), compared with 
MICs of 32–64 mg/mL for linezolid.26 
As for streptococci, MIC
90
 values for 
tedizolid in one study were 0.25 and 
0.5 mg/mL, both of which were within 
the susceptible range of the proposed 
breakpoints.20,21
Against anaerobes, the tedizolid 
MIC
90
 for Peptostreptococcus anaero-
bius, Peptostreptococcus micros, and 
Porphyromonas asaccharolytica was 
0.5 mg/mL—fourfold to eightfold 
lower than MIC
90
 values for linezol-
id.20 Tedizolid has also shown some 
activity against anaerobic gram- 
negative organisms. No breakpoints 
have been proposed for anaerobes.
Tedizolid has shown activity 
against acid-fast bacilli in in vitro 
studies. In one study, tedizolid was 
tested against 95 strains of Mycobac-
Table 1.
Inhibitory Activity of Tedizolida
Organism(s) MIC90 (mg/mL)
aMIC90 = minimum inhibitory concentration for 90% of isolates, MS = methicillin susceptible, MR = methicillin 
resistant, PI = penicillin intermediate, PR = penicillin resistant, VS = vancomycin susceptible, VR = vancomycin 
resistant.
Gram-positive bacteria
 Corynebacterium jeikeium21
 Listeria monocytogenes21
Staphylococcus species
 S. aureus (MS)20,21,28
 S. aureus (MR)20,21,28
Coagulase-negative staphylococci (MS)20,21
Coagulase-negative staphylococci (MR)20,21
Streptococcus species
 S. pneumoniae20,21
 S. pneumoniae (PI and PR)20,21,29
 S. agalactiae20,21
 S. pyogenes20,21
 Viridans group21
Enterococcus species
 E. faecalis (VS and VR)20,21
 E. faecium (VS)20,21
 E. faecium (VR)20,21
Gram-negative bacteria
 Haemophilus influenzae20,21
 Moraxella catarrhalis20,21
Anaerobes
 Bacteroides fragilis group20
 Clostridium perfringes20
 Peptostreptococcus species20
 Prevotella species20
0.50
0.25
0.25–0.50
0.25–1.0
0.50
0.50
0.25
0.25–0.50
0.25–0.50
0.25–0.50
0.25
0.50–1.0
0.50–1.0
0.50
16
4
4
2
0.5
4
terium tuberculosis, 34 of which were 
resistant to isoniazid or rifampin or 
both30; the MIC
50
 and MIC
90
 were 
0.25 and 0.5 mg/mL, respectively, 
for the evaluated isolates, including 
strains that were resistant to both 
isoniazid and rifampin. Tedizolid was 
also tested against Mycobacterium 
fortuitum, with the respective MIC
50
 
and MIC
90
 determined to be 1 and 
4 mg/mL.31 No breakpoints for acid-
fast bacilli have been proposed.
As for gram-negative respiratory 
pathogens, the tedizolid MIC
90
 was 
found to be 16 mg/mL for H. influen-
zae and 4 mg/mL for M. catarrhalis.20 
No breakpoints for these organisms 
have been proposed.
Development of resistance
While the extent of the develop-
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ment of resistance in clinical practice 
has not been determined, spontane-
ous resistance to tedizolid appears 
to be uncommon, as shown by in 
vitro studies. Bacterial strains asso-
ciated with elevated linezolid MICs 
generally have mutations in the 23S 
rRNA target as their mechanism 
of resistance.32 The four main sites 
of mutation are G2576T, T2500A, 
G2505A, and G2447T. An additional 
mechanism of resistance in staphy-
lococci is cfr, a transferable rRNA 
methyltransferase gene.33 The final 
possible mechanism of resistance 
to linezolid involves mutations in 
the ribosomal proteins L3 and L4 in 
streptococci.34 In one study by Locke 
et al.,35 the median rates of spontane-
ous mutation leading to decreased 
susceptibility to tedizolid were 1.1 × 
10–10 in an MSSA isolate and 1.9 × 
10–10 in a MRSA isolate; these rates 
were 16–18 times lower than have 
been reported with linezolid. The 
mechanism of resistance to tedizolid 
that developed spontaneously in 
the S. aureus isolates was a T2500A 
mutation in the 23S rRNA, whereas 
the development of spontaneous 
resistance to linezolid involved both 
G2576T and T2500A mutations as 
well as the ribosomal protein L3 mu-
tations Gly155Arg/Met169Leu and 
DPhe127-His146.35 At the end of 30 
serial passage tests, the tedizolid MIC 
for an MSSA isolate remained at 0.5 
mg/mL, compared with a linezolid 
MIC increase from 2 to 128 mg/mL.35 
After 30 passages, the tedizolid MIC 
of a MRSA isolate increased from 
0.25 to 2 mg/mL, compared with a 
linezolid MIC increase from 1 to 32 
mg/mL. The mutations that devel-
oped with tedizolid in the MRSA 
isolate were T2571C and G2576T in 
the 23S rRNA, with no L3 mutations. 
This represents a novel combination 
of mutations, as both mutations 
occurred together during the serial 
passages.
To test the activity of tedizolid 
against linezolid-resistant gram-
positive bacteria, an in vitro study 
was conducted using bacteria with 
well-characterized mechanisms of 
resistance.27 Overall, tedizolid was at 
least four times more potent than 
linezolid against gram-positive cocci 
that had the G2576T mutation, in-
hibiting over 88% of enterococci. 
The range of tedizolid MICs against 
cfr-positive staphylococci was 0.5 to 
8 mg/mL, compared with those of 
linezolid (8 to >32 mg/mL). If the 
same susceptibility breakpoints for 
linezolid were used for tedizolid, only 
1 Enterococcus and 13 staphylococcal 
isolates (11.7% of isolates) would be 
deemed nonsusceptible to tedizolid.27 
Furthermore, in strains tested against 
both tedizolid and linezolid, there 
were no tedizolid MIC increases in 
passaging series, whereas twofold 
linezolid MIC increases were noted 
for three strains.27
Pharmacokinetics
Administration. The prodrug te-
dizolid phosphate lacks antibacterial 
activity until converted into tedizo- 
lid, the active metabolite, by rapid 
hydrolysis of the phosphate ester 
bond in the plasma by phosphatas-
es.36,37 After oral administration, te-
dizolid is quickly and almost entirely 
absorbed, with a bioavailability of 
91% (90% confidence interval [CI], 
87–96%), which supports convenient 
i.v.-to-oral conversion.37 Concomi-
tant administration of tedizolid with 
a high-fat meal resulted in a lower 
geometric mean maximum plasma 
concentration (C
max
) (4.7 mg/mL 
versus 6.4 mg/mL in the fasting state) 
and a delay in the median time to 
C
max
 (t
max
) of six hours; moreover, 
the geometric mean area under the 
concentration–time curve (AUC
0–∞
) 
was no different in the fasting and fed 
states (79.9 and 81.8 mg · hr/mL, re-
spectively; geometric mean ratio, 1.02; 
90% CI, 98.2–106.8 mg · hr/mL).37 
Given that the pharmacokinetic or 
pharmacodynamic parameter most 
predictive of efficacy for tedizolid is 
the AUC:MIC ratio, it may be taken 
with or without food. 
Distribution. Based on a volume 
of distribution (V) in the plasma of 
108–143 L in adults, tedizolid has 
favorable penetration of tissues.37-40 
Sahre et al.39 specifically investigated 
tissue distribution of tedizolid in 12 
volunteers after a single 600-mg oral 
dose.39 They reported mean free-
drug AUC
0–12
 values of 4.9, 5.3, and 
5.9 mg · hr/mL in plasma, adipose, 
and muscle, respectively, resulting in 
an adipose:plasma AUC ratio of 1.1 
and a muscle:plasma AUC ratio of 
1.2. While the investigators reported 
the free-drug AUC over 12 hours 
(fAUC
0–12
) for tedizolid as signifi-
cantly higher in the muscle than in 
plasma and adipose tissue (p < 0.05), 
the differences were subtle and it 
cannot be assumed that they per-
sist throughout the 24-hour dosing 
interval. Additionally, even though 
the study used a dose three times the 
currently employed therapeutic dose 
of 200 mg, the total plasma AUC 
(57.1 mg · hr/mL) was lower than 
that reported in a previous pharma-
cokinetic study (79.3 mg · hr/mL).37 
Nonetheless, the tissue distribution 
of tedizolid supports its use for 
the treatment of skin and soft tissue 
infections.
The level of lung penetration of 
tedizolid into the epithelial lining 
fluid and alveolar macrophages was 
determined with the use of a Monte 
Carlo simulation.40 Twenty par-
ticipants received 200 mg of oral te-
dizolid phosphate for three days and 
underwent bronchoalveolar lavage 
at 2, 6, 12, or 24 hours after the last 
dose. The mean tedizolid concentra-
tions in epithelial lining fluid and al-
veolar macrophages at 24 hours were 
1.33 and 1.04 mg/mL, respectively, 
compared with a mean free plasma 
concentration of 0.043 mg/mL. Af-
ter 9999 Monte Carlo simulations, 
the mean AUC
0–24
 values were 106 
mg · hr/mL for epithelial lining fluid 
and 52.95 mg · hr/mL for alveolar 
macrophages.40 Assuming minimal 
protein binding in the lungs and 
an MIC of 0.5 mg/mL for S. aureus, 
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tedizolid achieves AUC:MIC ratios 
of 212 and 106 in the epithelial lin-
ing fluid and alveolar macrophages, 
respectively, which exceed the target 
mean fAUC:MIC ratio of 20 (similar 
to that of linezolid) for stasis achieve-
ment that was described in a neu-
tropenic mouse model of S. aureus 
pneumonia.22,40 Of note, according 
to animal models, the free-tedizolid 
AUC:MIC ratio for stasis in pulmo-
nary infections is nearly 60% less than 
that observed in soft tissue infections, 
which may be a reflection of the abil-
ity of oxazolidinones to concentrate in 
epithelial lining fluid given that line-
zolid also displays similar attributes.22
Metabolism. Metabolism of te-
dizolid occurs primarily by sulfation, 
with the drug being predominately 
eliminated as an inactive sulfate me-
tabolite in the feces and urine (81.5% 
and 18%, respectively). Moreover, 
less than 1% of tedizolid or tedizolid 
phosphate is excreted unchanged in 
the urine.37,41 Overall, the half-life 
ranges from 10.4 to 12.4 hours in 
adults, supporting once-daily dos-
ing.37,38 Since the efficacy of tedizolid 
is best correlated with free drug 
levels, it is important to note that 
tedizolid exhibits variable levels of 
protein binding, ranging from 80% 
to approximately 90%.39-41
The current tedizolid therapeutic 
dosing regimen of 200 mg per day is 
supported by animal studies wherein 
the maximal killing rate was compa-
rable for daily doses ranging from 
200 to 1200 mg.42 Pharmacokinetic 
modeling was conducted via nonlin-
ear mixed-effects modeling and 500 
Monte Carlo simulations using data 
from 175 patients enrolled in a Phase 
II dose-ranging study.43 The analysis 
demonstrated that tedizolid kinetics 
best fit within a two-compartment 
model. After oral administration, 
absorption occurs in an average of 45 
minutes and tedizolid enters into the 
central compartment.36,44 First-order 
intercompartmental distribution to 
the peripheral compartment occurs 
at an elimination rate of 12.7 hour–1 
and redistributes to the central com-
partment at 12.8 hour–1. Both human 
and animal studies determined that 
tedizolid exhibits nearly dose-linear 
increases in the AUC, whereas as-
cending doses did not result in dose-
proportional increases in C
max
.22,37,44
Several tedizolid pharmacoki-
netic studies have been conducted in 
healthy volunteers (Table 2). Oral or 
i.v. administration of a single 200-mg 
dose correlated with mean AUC
0-∞
 
values of 25.4 and 32.58 mg · hr/mL, 
respectively.37,38 In multiple-dose 
studies, steady-state tedizolid con-
centrations provided an AUC
0–24
 of 
22.5 mg · hr/mL after oral adminis-
tration. The steady-state AUC
0–24
 for 
intravenously administered tedizolid 
was higher, at 29.19 mg · hr/mL; in 
addition, after 15 days of adminis-
tration, the accumulation ratio (the 
ratio of the AUC on day 21 to the 
AUC on day 1) was 1.31.37 In general, 
the AUC for linezolid is two to three 
times that of tedizolid; however, the 
V and the half-life of tedizolid are 
approximately twice those of line-
zolid.37 Moreover, pharmacokinetic 
studies suggest higher accumula-
tion ratios with linezolid.37 Despite 
a lower AUC relative to linezolid, 
tedizolid achieves bacteriostasis at a 
lower AUC:MIC ratio.
The pharmacokinetics of tedizolid 
were demonstrated to be similar 
among healthy adults (including el-
derly persons) and adolescents in two 
studies by Dreskin et al.45,46 (Table 3). 
In the first study, elderly participants 
(mean age, 71.9 years) and younger 
controls (mean age, 33.37 years) 
were each given a single oral 200-mg 
dose of tedizolid phosphate.45 The 
estimated glomerular filtration rates 
(eGFRs) were 75 mL/min per 1.73 m2 
of body surface area for the elderly 
participants and 137 mL/min per 
1.73 m2 for the younger controls. 
Overall, the geometric mean AUC
0–∞
 
values for the elderly and control 
participants (33.2 and 29.3 mg · hr/mL, 
respectively) were similar, with a 
geometric mean ratio of 1.132 (90% 
CI, 0.954–1.343). In the second study, 
200 mg of tedizolid phosphate was 
given orally and intravenously to ad-
olescents 11–17 years of age (mean, 
14.5 years) and to historical
 
adult 
controls.46 After oral administration 
of tedizolid, the geometric mean 
AUC
0–∞
 values in younger versus 
older participants were similar (23.9 
mg · hr/mL versus 26 mg · hr/mL), at 
a ratio of 0.92 (90% CI, 0.72–1.18); 
there was even less difference in geo-
metric mean AUC
0–∞
 values after i.v. 
administration (27 mg · hr/mL versus 
28.4 mg · hr/mL; geometric mean 
ratio, 0.95; 90% CI, 0.77–1.17).46 
While no statistical comparison has 
been made, the half-life of tedizolid 
in adolescents versus older persons is 
shorter despite similar clearance.
Excretion. The effects of renal 
and hepatic impairment on tedizolid 
clearance were studied in two Phase 
I studies by Flanagan et al.47,48 (Table 
3). In the renal impairment study, a 
200-mg i.v. dose was given to par-
ticipants who were assigned to one 
of two groups according to eGFR val-
ues.47 The severe renal impairment 
group consisted of participants with 
an eGFR of less than 30 mL/min/1.73 
m2 who were not on hemodialysis, 
whereas the control group included 
those with an eGFR of ≥80 mL/
min/1.73 m2. The mean ± S.D. eGFR 
for the renal impairment group 
was 18.3 ± 5.4 mL/min/1.73 m2. No 
difference was noted between the 
renal impairment and control group 
geometric mean AUC
0–∞
 values (28.7 
mg · hr/mL versus 31.1 mg · hr/mL; 
geometric mean ratio, 0.93; 90% 
CI, 0.7–1.23); as a result, no dosing 
modifications are recommended for 
patients with renal impairment.
In the hepatic impairment study, 
a 200-mg oral dose of tedizolid was 
given to eight participants with 
moderate impairment (Child–Pugh 
scores of 7–9) and eight participants 
with severe impairment (Child–Pugh 
scores of 10–15) who were matched 
with control participants with nor-
mal hepatic function.48 For patients 
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with moderate hepatic impairment, 
the mean AUC
0–∞
 was 30.42 mg · hr/
mL, compared with a mean of 22.98 
mg · hr/mL in the controls. For pa-
tients with severe hepatic impair-
ment, the mean AUC
0–∞
 was 35.24 
mg · hr/mL, compared with a mean 
of 24.53 mg · hr/mL in the controls. 
Although the ratios of geometric 
mean AUC
0–∞
 values in the moder-
ate- and severe-impairment groups 
relative to the respective control 
groups were 1.22 (90% CI, 0.86–
1.72) and 1.34 (90% CI, 0.93–1.94), 
no significant difference was noted 
in patients with hepatic impair-
ment. Results from this single-dose 
pharmacokinetic study suggest that 
patients with moderate-to-severe 
hepatic impairment have an in-
creased tedizolid exposure of 22–
34% relative to patients with normal 
hepatic function, warranting close 
monitoring for potential adverse 
effects and toxicities, particularly 
until multidose studies describing 
accumulation in this population are 
presented or published.
Evidence of clinical efficacy. As 
with linezolid, the pharmacokinetic– 
pharmacodynamic parameter most 
predictive of bacterial killing and 
clinical efficacy with tedizolid  is the 
fAUC:MIC ratio.36 This was demon-
strated in a MRSA-infected neutro-
penic mouse thigh model wherein 
equally divided doses of tedizolid were 
given at 24-, 12-, or 6-hour intervals 
and their effects analyzed in a dose- 
fractionation study. The relation-
ships between microbiological effect 
and the fAUC:MIC ratio, the free-
drug time above the MIC (ft>MIC), 
and the free-drug C
max
:MIC ratio 
(fC
max
:MIC) were evaluated with 
regression analysis; furthermore, 
the fAUC:MIC ratio maintained 
the highest level of correlation (r2 = 
0.984) relative to the fC
max
:MIC ratio 
(r2 = 0.757) and the ft>MIC (r2 = 
0.624).
The target AUC:MIC ratio for te-
dizolid has been described in animal 
models but not in human subjects 
to date. In the neutropenic mouse 
thigh model described above, stasis 
effect (i.e., reduction in bacterial 
density to the baseline level of 5.7 
log
10
 colony-forming units [CFU]/g) 
was attained within 24 hours at 
fAUC:MIC ratios of 49.1 and 47.1 for 
MSSA and MRSA, respectively.36 At 
similar fAUC:MIC ratios, linezolid 
did not achieve stasis; however, the 
mean target linezolid AUC:MIC ratio 
to achieve stasis for S. aureus is 83.36,49 
In an aortic valve endocarditis 
model, rabbits were infected with 
107 CFU/mL of MRSA (MIC, 0.1 
mg/mL).50 Tedizolid significantly re-
duced the vegetative bacterial burden 
compared with no treatment (to 7.7 
log
10
 CFU/g versus 6 log
10
 CFU/g, 
p < 0.05); however, daptomycin de-
creased the bacterial load more than 
tedizolid (to 3.5 log
10
 CFU/g versus 
6 log
10
 CFU/g, p = 0.05). At a higher 
bacterial burden (108 CFU/mL), te-
dizolid reduced the vegetative density 
to 8.3 and 8.0 log
10
 CFU/g when given 
at doses sufficient to achieve AUC
0–24
 
values of 47 and 85 mg · hr/mL, re-
spectively, but vancomycin reduced 
the bacterial load to a larger extent 
(to 6.5 log
10
 CFU/g) than any tested 
tedizolid doses. When tedizolid was 
administered to achieve an AUC
0–24
 
of 24 mg · hr/mL, the resultant bacte-
rial load was comparable to that seen 
with no treatment (9.3 and 9.2 log
10
 
CFU/g, respectively).
Tedizolid was compared with 
vancomycin and linezolid in a mu-
rine model of catheter-related MSSA 
biofilm infection.51 Reductions in 
biofilm bacterial cell count were seen 
with tedizolid compared with no 
treatment or treatment with either 
linezolid or vancomycin; after three 
days, biofilm cell counts were 5.49, 
7.5, 7.7, and 7.52 log
10
 CFU/catheter, 
respectively (p < 0.001 for all com-
parisons to tedizolid).
Clinical efficacy
The clinical efficacy of tedizolid 
in ABSSSI has been evaluated in one 
Phase II and two Phase III trials.
Phase II study. The efficacy of 
tedizolid was first evaluated in the 
previously mentioned multicenter 
dose-ranging Phase II study in pa-
tients with ABSSSI.44 Subjects were 
given 200, 300, or 400 mg orally once 
daily for 5–7 days. The decision to 
choose that treatment duration was 
based on previous data from a Phase 
I trial in which tedizolid at a dose 
of 200 mg given over one week was 
shown to be safe and effective when 
compared with doses of 300 or 400 
mg given over a three-week period.52 
The primary endpoint of the study 
was the clinical response rate of each 
group at the test of cure (TOC) visit, 
defined as 7–14 days after treatment. 
Secondary objectives included cure 
rates at the end-of-therapy visit, mi-
crobiological response rates, safety 
measures in each dosing group, and 
the absorption and disposition of 
the drug. Of the 192 patients en-
rolled, 188 patients (referred to as the 
clinically modified intent-to-treat 
population [MITT]) were random-
ized 1:1:1 to the three given doses of 
tedizolid. Although inhospital and 
outpatients were eligible for inclu-
sion, no hospitalized patients were 
enrolled in the study. Over 85% 
(n = 164) of the randomized patients 
who received the minimal amount 
of study drug therapy and were 
evaluated for cure at the TOC visit 
were considered clinically evaluable. 
Infection types included abscesses, 
surgical or posttraumatic wounds, 
and cellulitis. Patients with diabetic 
foot ulcer, gangrene, perirectal ab-
scesses, burns, decubitus, necrotizing 
fasciitis, endocarditis, osteomyelitis, 
ischemic ulcers, and infections near 
a catheter site or a prosthetic device 
were excluded from the study.44 The 
most frequently isolated pathogen 
was S. aureus (90.3%), of which 
80.5% were found to be MRSA. 
The overall clinical cure rates were 
95.7% in those who completed the 
treatment in the clinically evaluable 
population and 87.8% in the MITT 
population. The treatment response 
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rates did not differ among the three 
groups regardless of the type of in-
fection. Additionally, the microbio-
logical eradication rates were similar 
across all three groups, ranging from 
92.6% to 100% in MRSA-infected 
patients and from 88.9% to 100% 
in MSSA-infected patients. All other 
recovered pathogens were completely 
eradicated. Hence, the 200-mg dose of 
oral tedizolid phosphate administered 
once daily for 5–7 days was deter-
mined to be the lowest effective dose.
Phase III studies. ESTABLISH-1. 
The Efficacy and Safety of 6-day Oral 
Tedizolid in Acute Bacterial Skin 
and Skin Structure Infections ver-
sus 10-day Oral Linezolid Therapy 
(ESTABLISH-1) study was a Phase 
III, randomized, double-blind, non-
inferiority trial conducted at 81 
centers in North America, Latin 
America, and Europe to establish the 
safety and efficacy of orally admin-
istered tedizolid 200 mg once daily 
for 6 days versus orally administered 
linezolid 600 mg twice daily for 10 
days in the treatment of ABSSSI.53 
The 6-day duration of tedizolid ther-
apy was chosen on the basis of the 
results of the previously mentioned 
Phase II study, while a duration of 10 
days was chosen for linezolid based 
on the FDA-approved duration of 
therapy. Enrolled patients in both 
groups received three tablets daily 
for a total of 10 days. Patients in the 
tedizolid group received one tablet of 
tedizolid plus one tablet of placebo, 
followed by one tablet of placebo 12 
hours later, on days 1–6 and two tab-
lets of placebo, followed by another 
tablet of placebo 12 hours later, on 
days 7–10. Patients in the linezolid 
group received one tablet of linezolid 
plus one tablet of placebo, followed 
by one tablet of linezolid 12 hours 
later, for 10 days. The noninferior-
ity margin was predefined at 10%. 
The primary endpoint of the study 
was the detection of early clinical 
response at the 48- to 72-hour clini-
cal evaluation. Clinical response was 
considered positive if there were no 
increase in the lesion surface area 
from baseline and no fever (as in-
dicated by an oral temperature of 
≤36.7 °C). The absence of fever was 
confirmed by another measurement 
performed 24 hours after the 48- to 
72-hour assessment. The secondary 
endpoints included rates of sustained 
clinical response at the end of treat-
ment (defined as 11 days after the 
administration of the first dose) for 
all randomized patients at the end of 
therapy and at the posttherapy evalu-
ation 7–14 days after the end of treat-
ment, using intent-to-treat (ITT) 
and “clinically evaluable” analyses; 
these endpoints were measured us-
ing the same variables as the primary 
endpoints. Patients were considered 
ineligible for study participation if 
they had uncomplicated ABSSSI or 
the infection was associated with a 
vascular catheter site, a “non-clean 
surgery,” thrombophlebitis, or a 
suspected or documented gram-
negative pathogen; enrolled patients 
who were found to have received sys-
temic or topical antibiotics effective 
against gram-positive bacteria within 
96 hours before starting the study 
drug were excluded from the data 
analysis. A total of 667 patients were 
randomly assigned to receive either 
tedizolid or linezolid, of whom 90% 
completed the study. After random-
ization, 3 patients from each group 
were excluded due to a nonspecified 
confounding surgery. The types of 
surgeries performed were not speci-
fied in the study, and the use of an-
tibiotic prophylaxis was not noted. 
The ITT population included 667 
patients, while the clinically evalu-
able population included 559. Based 
on data for the ITT population, the 
distributions of infection types were 
comparable in the two treatment 
groups. Infection types were catego-
rized as follows: cellulitis/erysipelas, 
major cutaneous abscess, and infect-
ed wound. Most isolated pathogens 
(98.6%) were gram-positive aerobes. 
The most common pathogen iso-
lated from infection sites was S. au-
reus (82.8%). MRSA was identified in 
42.1% of infections in the tedizolid 
group and 43.1% of infections in the 
linezolid group. Of note, the highest 
MIC value for tedizolid in this study 
was 0.5 mg/mL, which may influence 
FDA’s decision on breakpoint values 
given that Brown and Traczewski21 
have recommended a susceptible 
breakpoint of ≤2 mg/mL.
The response rates at the 48- to 
72-hour assessment (in the primary 
efficacy ITT analysis) were 79.5% 
(95% CI, 74.8–83.7%) in the te-
dizolid phosphate group and 79.4% 
(95% CI, 74.7–83.6%) in the line-
zolid group, where the noninferior-
ity margin was predefined at 10% (a 
treatment difference of 0.1% [95% 
CI, –6.1% to 6.2%]). Of note, 11.1% 
and 9.6% of patients in the tedizolid 
phosphate and linezolid groups, 
respectively, were not included in 
the primary outcome results due to 
missing temperature data or were 
followed up outside the prespecified 
time window of 48–72 hours. How-
ever, few patients in either group 
(8.1% and 10.4% in the tedizolid 
phosphate and linezolid groups, 
respectively) were considered non-
responders because of increases in 
temperature or lesion size. All sec-
ondary outcome measures showed 
the noninferiority of tedizolid phos-
phate to linezolid. For instance, the 
rates of sustained clinical response 
at the end of treatment were 69.3% 
(95% CI, 64.0–74.2%) in the te-
dizolid group and 71.9% (95% CI, 
69.3–71.9%) in the linezolid group; 
the corresponding values in the 
clinically evaluable end-of-treatment 
analysis set were 80.2% (95% CI, 
80.0–84.8%) and 81.1% (95% CI, 
76.1–85.5%), respectively. Outcomes 
for subgroups were also analyzed. It 
is important to note that treatment 
response rates at the early clinical 
evaluation (i.e., 48- to 72-hour as-
sessment) and end-of-treatment 
time points were lower for cellulitis/
erysipelas than for the other infec-
tion types; this could be attributed to 
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the fact that not all primary cellulitis 
lesions were cultured (gram-positive 
aerobes were isolated from only 31% 
of primary cellulitis lesions, whereas 
they constituted 85% of the patho-
gens isolated from abscesses or skin 
wounds). Notably, at posttherapy 
evaluation, the clinical response rates 
were similar with both treatments 
among subgroups of patients infect-
ed with MRSA (85.2% in the tedizo- 
lid phosphate group versus 85.6% in 
the linezolid group) or MSSA (88% 
with tedizolid versus 94.3% with li-
nezolid). This study demonstrated a 
statistically significant noninferiority 
of tedizolid phosphate 200 mg orally 
once a day for 6 days relative to line-
zolid 600 mg orally twice daily for 10 
days in the treatment of ABSSSI.
ESTABLISH-2. Another Phase 
III randomized, double-blind, mul-
ticenter study was conducted at 
95 sites in Europe, Australia, New 
Zealand, South Africa, and North 
and South America comparing the 
efficacy and safety of 6 days of i.v.-
to-oral tedizolid therapy and 10 
days of i.v.-to-oral linezolid therapy 
for ABSSSI.54 The enrolled patients 
either received 200 mg of tedizolid 
once a day for 6 days followed by 
4 days of placebo use or received 
600 mg of linezolid twice a day for 
10 days. In both groups, the switch 
from i.v. to oral administration was 
handled by the clinical investigator 
on or after the second day of treat-
ment. The primary outcome was the 
rate of early response to 6-day i.v.-
to-oral tedizolid versus 10-day i.v.-
to-oral linezolid at 48–72 hours after 
the start of therapy, with a predefined 
noninferiority margin of 10%. The 
clinical response was considered 
positive if there was a 20% decrease 
from baseline in lesion area at 48–72 
hours. The secondary outcomes were 
the rate of objective sustained clinical 
response at the end-of-therapy eval-
uation in the ITT analysis set, which 
included all randomized patients; the 
rate of objective sustained clinical 
response at the end of therapy; and 
investigators’ assessment of clinical 
response at 7–14 days after the end of 
therapy. The number of patients en-
rolled, the percentage of patients in 
each of the treatment groups, and the 
infection types were similar to those 
in the first ESTABLISH study. For in-
stance, patients with uncomplicated 
skin and skin structure infections, 
systemic exposure to an antibiotic 
active against gram-positive bacteria 
within 96 hours before administra-
tion of a study drug, severe sepsis 
or documented bacteremia, severe 
renal or hepatic disease, infections 
close to a prosthetic device, or proxi-
mal treatment with monoamine 
oxidase (MAO) inhibitors, selective 
serotonin-reuptake inhibitors, or 
serotonin-receptor agonists were 
excluded. A total of 666 patients 
were randomly assigned to receive 
either tedizolid or linezolid. As in 
ESTABLISH-1, the types of in-
fections were cellulitis/erysipelas, 
major cutaneous abscess, and in-
fected wounds. The reported isolated 
pathogens were gram-positive aer-
obes. The most common pathogen 
isolated from the infection site was 
S. aureus (80.2% of isolates in the 
tedizolid group and 82.7% of isolates 
in the linezolid group). MRSA was 
identified in 26.9% of infections in 
the tedizolid group and 27.7% of 
infections in the linezolid group. The 
rest of the isolated pathogens were 
Streptococcus species. 
The response rates at the 48- to 
72-hour assessment (per the primary 
efficacy ITT analysis, which was de-
signed to detect a 20% decrease in le-
sion area) were 85.2% in the tedizolid 
phosphate group and 82.6% in the 
linezolid group, an absolute treat-
ment difference of 2.6 (95% CI, 
–3.0 to 8.2). All secondary efficacy 
endpoints measured at both the end-
of-therapy and posttreatment evalu-
ations were met; in particular, the 
rates of sustained clinical response 
at the end of therapy were 87% in 
the tedizolid group and 88% in the 
linezolid group (absolute percentage 
difference, –1.0; 95% CI, –6.1 to 4.1), 
and clinical response at 7–14 days 
was reported to be 88% and 87.7% 
in the tedizolid and linezolid groups, 
respectively (absolute percentage dif-
ference, 0.3; 95% CI, –4.8 to 5.3).
These two Phase III trials have 
demonstrated the noninferiority of 
tedizolid phosphate 200 mg once 
daily for 6 days relative to linezolid 
600 mg twice daily for 10 days for the 
treatment of ABSSSI.
Safety and tolerability
The safety of tedizolid has been 
evaluated in one Phase II and two 
Phase III trials. In the Phase II clini-
cal trial, treatment-emergent adverse 
events were reported in 69.1% of 
the patients, with the majority of 
these adverse events graded as mild 
(72.3%) or moderate (24.6%) in 
severity.44 However, none of the ad-
verse events resulted in drug discon-
tinuation, and there was no apparent 
dose-related toxicity.44,55 Nausea was 
the most frequently reported adverse 
effect in all three studies (16.5% 
overall rate). Other adverse events 
such as diarrhea, vomiting (10.1%), 
and headache (11.2%) were reported 
at a lower percentage. No significant 
thrombocytopenia (either dose or 
time dependent) was observed with 
tedizolid in this Phase II trial. This 
reaffirms the results of a Phase I trial 
that compared different doses of te-
dizolid (200, 300, and 400 mg) with 
the use of placebo or oral linezolid 
600 mg twice daily; in that study, the 
200- and 300-mg doses had effects 
on platelets similar to those seen with 
placebo use, whereas the effect of 
the 400-mg dose on platelet counts 
was similar to that of linezolid, with 
thrombocytopenia reported in 2.4% 
of cases. Also, no adverse cardiac 
events were observed.44,56
In the first of the Phase III trials 
summarized above, the safety profile 
of tedizolid appeared to be similar 
to that of linezolid. Forty percent 
of patients experienced treatment-
emergent adverse events in the te-
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dizolid group, compared with 43% 
in the linezolid group.53 The adverse 
events were mostly mild or moderate 
in severity. Two patients in each treat-
ment group were withdrawn from the 
study. Three out of 4 left the study 
due to one or more gastrointestinal- 
related adverse events, and 1 patient 
was withdrawn due to severe osteo-
myelitis. Gastrointestinal adverse 
events such as nausea, diarrhea, vom-
iting, and dyspepsia were more dom-
inant in the linezolid group (25.4%) 
than the tedizolid group (16.3%), 
with diarrhea being predominant 
in both groups. Other treatment-
emergent adverse events manifested 
in infections and infestations (cu-
mulative rate, 15.1% with tedizolid 
versus 11% with linezolid) and ner-
vous system disorders (10.9% versus 
9.6%). Thrombocytopenia, which is 
a frequently reported adverse effect 
of linezolid, was observed in 2.3% of 
patients receiving tedizolid and 4.9% 
of patients receiving linezolid (p = 
0.127).53,57 However, in both groups 
platelet counts recovered with no 
intervention and without stopping 
antibiotic therapy. It is also impor-
tant to note that 11 of 22 patients 
(50%) with thrombocytopenia were 
hepatitis C positive. 
One study has been conducted to 
determine the potential impact of 
tedizolid on Q-Tc interval prolonga-
tion.58 It was a blinded, randomized, 
four-period crossover study compar-
ing the effect of tedizolid 200 or 1200 
mg or moxifloxacin 400 mg (active 
control) versus placebo on the Q-T 
interval corrected for heart rate using 
Fridericia’s formula and other elec-
trocardiogram (ECG) measurements 
in 48 healthy adult men and women. 
This study showed that tedizolid at 
either evaluated dose had no clini-
cal effect on heart rate or other ECG 
measures such as the P-R, QRS, and 
QTcF intervals. 
Drug interactions
As previously discussed, tedizolid 
is primarily metabolized hepatically 
but does not exhibit an affinity for 
any of the cytochrome P-450 enzyme 
pathways; moreover, the potential 
for drug–drug interactions is mini-
mal. However, as with linezolid, one 
concern with this second-generation 
oxazolidinone is the weak, reversible 
MAO-A and MAO-B inhibition seen 
during in vitro research.59
To elucidate the extent to which 
tedizolid produces MAO inhibition, 
Flanagan et al.59 conducted studies 
in both animals and healthy human 
volunteers. In vitro, tedizolid inhibits 
50% of MAO-A and MAO-B activ-
ity, on average, at 8.7 and 5.7 mM, 
respectively, whereas linezolid has a 
higher 50% inhibitory concentra-
tion (IC
50
) for MAO-A (46.0 mM) 
but a lower IC
50
 for MAO-B (2.1 
mM). Overall, both agents are two to 
three orders of magnitude less potent 
MAO inhibitors than clorgyline (for 
MAO-A) and deprenyl (for MAO-B), 
for which the reported IC
50
 values 
are 2.1 and 12 nM, respectively.39 To 
determine the potential of tedizolid 
to produce serotonin receptor 2A 
stimulation, a murine head-twitch 
model was employed. The animal 
model revealed that tedizolid lacked 
serotonergic activity at all tested dos-
es, including those producing plasma 
concentrations that were nearly 25 
times higher than those produced by 
therapeutic human doses.59
In a randomized, double-blind, 
placebo-controlled crossover study, 
30 healthy human subjects were 
given either 200 mg of tedizolid 
phosphate or a placebo, with the 
introduction of 25 mg of tyramine 
to both groups on the third day and 
escalation of the tyramine dose by 50 
mg each day until a maximum of 575 
mg or a systolic blood pressure (SBP) 
increase of ≥30 mm Hg59; there was a 
two-day washout period before sub-
jects were switched to the alternative 
regimen. Of the 30 subjects, 7 experi-
enced an increase in SBP of ≥30 mm 
Hg while receiving both tedizolid and 
the placebo at median tyramine dos-
es of 325 and 425 mg, respectively. As 
a benchmark, a meal is considered 
tyramine rich if it contains at least 40 
mg of tyramine.60
In a second crossover study, pseu-
doephedrine was administered to 36 
subjects after five days of tedizolid or 
placebo use, with a two-day washout 
period between regimens.59 There 
were no significant between-group 
differences in the least-squares mean 
maximum change from baseline in 
SBP (11.6 mm Hg with tedizolid 
versus 12.1 mm Hg with placebo, 
p = 0.7309), diastolic blood pressure 
(6.7 mm Hg versus 6.8 mm Hg, p = 
0.8966), or heart rate (13.6 beats/min 
versus 15.2 beats/min, p = 0.1689); 
furthermore, no clinically relevant 
ECG changes were seen.
Overall, based on the available 
animal and human data, tedizolid 
does not appear to require any di-
etary tyramine restrictions, nor does 
it increase blood pressure or heart 
rate when combined with pseu-
doephedrine, which are two safety 
issues encountered with linezolid.11 
Moreover, while it appears that a 
clinically significant interaction with 
concomitantly administered MAO 
inhibitors or selective serotonin 
reuptake inhibitors is unlikely, the 
use of tedizolid in clinical practice 
outside of controlled clinical trials 
will provide clarification as to the 
potential for such interaction.
Dosing and administration
The dosing regimen that was used 
in the Phase III trials was 200 mg of 
tedizolid administered either orally 
or intravenously once daily.53,54 
Oral tedizolid may be taken with or 
without food. In clinical studies, the 
i.v. formulation has been given as 
200 mg in 250 mL of 0.9% sodium 
chloride injection infused over 60 
minutes.38,54 No dosing adjustments 
are currently recommended for pa-
tients with any level of renal impair-
ment.47 Although no alterations are 
currently suggested for patients with 
moderate or severe liver dysfunc-
tion, increases in tedizolid exposure 
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and half-life have been observed in 
this population, and close monitor-
ing of adverse effects and toxicities is 
recommended.48 
Summary
With the growing concerns of 
resistance and treatment failure 
with vancomycin, new alternative 
antibiotics are needed for multidrug-
resistant gram-positive infections. 
Since 2000, several such agents have 
been approved by FDA, including 
linezolid, daptomycin, tigecycline, 
telavancin, and ceftaroline. Unfortu-
nately, reports of resistance to these 
antibiotics were published shortly af-
ter their release to the market.13-15,61,62 
Some additional limitations of these 
medications include the potential 
for adverse drug events and drug 
interactions (especially with line-
zolid and telavancin), the lack of oral 
dosage forms (all except linezolid), 
and the need for multiple doses 
per day (linezolid, tigecycline, and 
ceftaroline). These limitations have 
led to increased calls for drug devel-
opment and expansion of the exist-
ing arsenal by several groups, includ-
ing the Infectious Diseases Society 
of America and the World Health 
Organization.63-66
Tedizolid is a second-generation 
oxazolidinone that has demonstrat-
ed potent in vitro activity against 
multidrug-resistant gram-positive 
pathogens including MRSA, VRE, 
and penicillin-resistant S. pneu-
moniae, including linezolid-resistant 
strains.20-29 The pharmacodynamic 
variable most predictive of bacte-
rial killing and clinical efficacy is 
the fAUC:MIC ratio.36 Of note, even 
though the MICs of tedizolid are 
several dilutions lower than those 
of linezolid for most gram-positive 
strains, the serum drug concentra-
tion and AUC of tedizolid are also 
notably lower, which limit the ability 
to compare the agents directly. Due 
to its long half-life, tedizolid only 
needs to be given once daily, and its 
high oral bioavailability (>90%) al-
lows for easy conversion from an i.v. 
to an oral formulation.37,38,53,54 Initial 
studies have shown that tedizolid 
may not have the same potential for 
interaction with serotonergic agents 
or impact on thrombocytopenia as li-
nezolid44,53,56,59; however, this remains 
to be proven in a larger population of 
patients with various risk factors or 
longer durations of therapy.
Tedizolid has demonstrated ef-
ficacy and safety in two Phase III 
trials for the treatment of ABSSSI.53,54 
Compared with linezolid, tedizolid 
was statistically noninferior in terms 
of early clinical response (i.e., within 
48–72 hours of initiation of therapy) 
and sustained clinical response at the 
end of treatment; treatment-related 
adverse events were also similar 
between groups. In October 2013, 
Cubist Pharmaceuticals submitted 
an NDA to FDA seeking approval 
of tedizolid for the treatment of 
ABSSSI.16 Additional studies are be-
ing planned in patients with HABP/
VABP and bacteremia.16,67
Even though tedizolid appears to 
have many properties of an ideal an-
timicrobial (in vitro activity against 
multidrug-resistant bacteria, i.v. 
and oral formulations, and once-
daily dosing), there remain questions 
about its optimal role in therapy that 
may only be answered with regula-
tory approval and (if approval is 
granted) wide use in populations 
outside of the current clinical tri-
als. Even though the large V and 
tissue penetration make tedizolid a 
good candidate for pulmonary and 
skin infections, this large V coupled 
with high protein binding also leads 
to a low free serum concentration, 
which may limit the drug’s efficacy 
in patients with bacteremia (as is the 
case with tigecycline). Also, less than 
1% of the active form of tedizolid 
is excreted unchanged in the urine, 
which may limit the drug’s clinical 
utility with regard to urinary tract 
infections. Results from additional 
clinical studies addressing these 
other prospective indications, as well 
as cost-of-therapy issues, will help 
determine tedizolid’s place within 
the current treatment paradigm for 
gram-positive infections.
Conclusion
Tedizolid is an investigational oxa-
zolidinone antibiotic for the treat-
ment of multidrug-resistant gram-
positive infections such as MRSA, 
Streptococcus pneumoniae, and VRE, 
including some linezolid-resistant 
strains.
References
1. Klein E, Smith DL, Laxminarayan R. 
Hospitalizations and deaths caused by 
methicillin-resistant Staphylococcus au-
reus, United States, 1999–2005. Emerg 
Infect Dis. 2007; 13:1840-6.
2. Klevens RM, Morrison MA, Nadle J et 
al. Invasive methicillin-resistant Staphy-
lococcus aureus infections in the United 
States. JAMA. 2007; 298:1763-71.
3. Kallen AJ, Mu Y, Bulens S et al. Health 
care–associated invasive MRSA infec-
tions, 2005–2008. JAMA. 2010; 304:641-
7.
4. Tenover FC, Moellering RC Jr. The ratio-
nale for revising the Clinical and Labo-
ratory Standards Institute vancomycin 
minimal inhibitory concentration inter-
pretive criteria for Staphylococcus aureus. 
Clin Infect Dis. 2007; 44:1208-15.
5. Soriano A, Marco F, Martínez JA et al. 
Influence of vancomycin minimum in-
hibitory concentration on the treatment 
of methicillin-resistant Staphylococcus 
aureus bacteremia. Clin Infect Dis. 2008; 
46:193-200.
6. Musta AC, Riederer K, Shemes S et al. 
Vancomycin MIC plus heteroresistance 
and outcome of methicillin-resistant 
Staphylococcus aureus bacteremia: trends 
over 11 years. J Clin Microbiol. 2009; 
47:1640-4.
7. Van Hal SJ, Lodise TI, Paterson DL. 
The clinical significance of vancomycin 
minimum inhibitory concentrations in 
Staphylococcus aureus infections: a sys-
tematic review and meta-analysis. Clin 
Infect Dis. 2012; 54:755-71.
8. Murray BE. Vancomycin-resistant en-
terococcal infections. N Engl J Med. 2000; 
342:710-21.
9. Ramsey AM, Zilberberg MD. Secu-
lar trends of  hospitalization with 
vancomycin‐resistant enterococcus in-
fection in the United States, 2000–2006. 
Infect Control Hosp Epidemiol. 2009; 
30:184-6.
10. Cetinkaya Y, Falk P, Mayhall CG. 
Vancomycin-resistant enterococci. Clin 
Microb Rev. 2000; 13:686-707.
11. Zyvox (linezolid) package insert. New 
York: Pharmacia & Upjohn; 2013 May.
CLINICAL REVIEW Tedizolid
632 Am J Health-Syst Pharm—Vol 71  Apr 15, 2014
12. Paladino JA. Linezolid: an oxazolidinone 
antimicrobial agent. Am J Health-Syst 
Pharm. 2002; 59:2413-25.
13. Tsiodras S, Gold HS, Sakoulas G et al. 
Linezolid resistance in a clinical isolate of 
Staphylococcus aureus. Lancet. 2001; 358: 
207-8.
14. Gonzales RD, Schreckenberger PC, 
Graham MB et al. Infections due to 
vancomycin-resistant Enterococcus fae-
cium resistant to linezolid. Lancet. 2001; 
357:1179.
15. Sánchez García M, De la Torre MA, 
Morales G et al. Clinical outbreak of 
linezolid-resistant Staphylococcus aureus 
in an intensive care unit. JAMA. 2010; 
303:2260-4.
16. Cubist Pharmaceuticals, Inc. Cubist 
announces submission of new drug ap-
plication for investigational antibiotic 
tedizolid for treatment of serious skin 
infections. http://investors.cubist.com/
file.aspx?IID=4093793&FID=20265968 
(accessed 2013 Oct 25).
17. United States Adopted Names Council. 
Tedizolid. www.ama-assn.org/resources/
doc/usan/tedizolid.pdf (accessed 2013 
Jun 29).
18. Bozdogan B, Appelbaum PC. Oxa-
zolidinones: activity, mode of action, and 
mechanism of resistance. Int J Antimicrob 
Agents. 2004; 23:113-9.
19. Locke JB, Finn J, Hilgers M et al. 
Structure-activity relationships of diverse 
oxazolidinones for linezolid-resistant 
Staphylococcus aureus strains possess-
ing the cfr methyltransferase gene or 
ribosomal mutations. Antimicrob Agents 
Chemother. 2010; 54:5337-43.
20. Schaadt R, Sweeney D, Sinabarger D et 
al. In vitro activity of TR-700, the active 
ingredient of the antibacterial prodrug 
TR-701, a novel oxazolidinone antibacte-
rial agent. Antimicrob Agents Chemother. 
2009; 53:3236-9.
21. Brown SD, Traczewski MM. Compara-
tive in vitro antimicrobial activities of 
torezolid (TR-700), the active moiety of 
a new oxazolidinone, torezolid phosphate 
(TR-701), determination of tentative 
disk diffusion interpretive criteria, and 
quality control ranges. Antimicrob Agents 
Chemother. 2010; 54:2063-9.
22. Lepak AJ, Marchillo K, Pichereau S et al. 
Comparative pharmacodynamics of the 
new oxazolidinone tedizolid phosphate 
and linezolid in a neutropenic murine 
Staphylococcus aureus pneumonia model. 
Antimicrob Agents Chemother. 2012; 
56:5916-22.
23. Keel RA, Tessier PR, Nicolau DP. Com-
parative efficacies of human simu-
lated exposures of tedizolid and linezolid 
against Staphylococcus aureus in the mu-
rine thigh infection model. Antimicrob 
Agents Chemother. 2012; 56:4403-7.
24. Livermore DM, Mushtaq S, Warner 
M et al. Activity of oxazolidinone TR-
700 against linezolid-susceptible and 
–resistant staphylococci and entero-
cocci. J Antimicrob Chemother. 2009; 
63:713-5.
25. Rodriguez-Avial I, Culebras E, Betriu C et 
al. In vitro activity of tedizolid (TR-700) 
against linezolid-resistant staphylococci. 
J Antimicrob Chemother. 2012; 67:167-9.
26. Shaw KJ, Poppe S, Schaadt R et al. In 
vitro activity of TR-700, the antibacterial 
moiety of the prodrug TR-701, against 
linezolid-resistant strains. Antimicrob 
Agents Chemother. 2008; 52:4442-7.
27. Jones RN, Moet GJ, Sader HS et al. TR-
700 in vitro activity against and resistant 
mutation frequencies among gram- 
positive pathogens. J  Antimicrob 
Chemother. 2009; 63:716-20.
28. Prokocimer P, Bien P, DeAnda C et al. In 
vitro activity and microbiological effi-
cacy of tedizolid (TR-700) against gram- 
positive clinical isolates from a phase 2 
study of oral tedizolid phosphate (TR-
701) in patients with complicated skin 
and skin structure infections. Antimicrob 
Agents Chemother. 2012; 56:4608-13.
29. Choi S, Im W, Bartizal K. Activity of 
tedizolid phosphate (TR-701) in murine 
models of infection with penicillin-
resistant and penicillin-sensitive Strep-
tococcus pneumoniae. Antimicrob Agents 
Chemother. 2012; 56:4713-7.
30. Vera-Cabrera L, Gonzalez E, Rendon A 
et al. In vitro activities of DA-7157 and 
DA-7218 against Mycobacterium tubercu-
losis and Nocardia brasiliensis. Antimicrob 
Agents Chemother. 2006; 50:3170-2.
31. Cynamon MH, Sklaney M. In vitro ac-
tivities of tedizolid compared to linezolid 
against Mycobacterium fortuitum. Paper 
presented at 52nd Interscience Confer-
ence on Antimicrobial Agents and Che-
motherapy. San Francisco, CA; 2012.
32. Meka VG, Gold HS. Antimicrobial resis-
tance to linezolid. Clin Infect Dis. 2004; 
39:1010-5.
33. Mendes RE, Deshpande LM, Castanheira 
M et al. First report of cfr-mediated resis-
tance to linezolid in human staphylococ-
cal clinical isolates recovered in the Unit-
ed States. Antimicrob Agents Chemother. 
2008; 52:2244-6.
34. Feng J, Lupien A, Gingras H et al. Ge-
nome sequencing of linezolid-resistant 
Streptococcus pneumoniae mutants re-
veals novel mechanism of resistance. 
Genome Res. 2009; 19:1214-23.
35. Locke JB, Hilgers M, Shaw KJ. Novel ri-
bosomal mutations in Staphylococcus au-
reus strains identified through selection 
with the oxazolidinones linezolid and 
torezolid (TR-700). Antimicrob Agents 
Chemother. 2009; 53:5265-74.
36. Louie A, Liu W, Kulawy R et al. In vivo 
pharmacodynamics of torezolid phos-
phate (TR-701), a new oxazolidinone 
antibiotic, against methicillin-susceptible 
and methicillin-resistant Staphylococcus 
aureus strains in a mouse thigh infection 
model. Antimicrob Agents Chemother. 
2011; 55:3453-60.
37. Flanagan SD, Bien PA, Munoz KA et al. 
Pharmacokinetics of tedizolid following 
oral administration: single and multiple 
dose, effect of food, and comparison of 
two solid forms of the prodrug. Phar-
macotherapy. Epub ahead of print. 2013 
Aug 7.
38. Bien P, Prokocimer P, Muñoz K et al. Ab-
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